Literature DB >> 27767098

A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2.

Kristian Jensen1, Rikke Krusenstjerna-Hafstrøm1, Jesper Lohse1, Kenneth H Petersen1, Helene Derand1.   

Abstract

In clinical routine pathology today, detection of protein in intact formalin-fixed, paraffin-embedded tissue is limited to immunohistochemistry, which is semi-quantitative. This study presents a new and reliable quantitative immunohistochemistry method, qIHC, based on a novel amplification system that enables quantification of protein directly in formalin-fixed, paraffin-embedded tissue by counting of dots. The qIHC technology can be combined with standard immunohistochemistry, and assessed using standard bright-field microscopy or image analysis. The objective was to study analytical performance of the qIHC method. qIHC was tested under requirements for an analytical quantitative test, and compared with ELISA and flow cytometry for quantitative protein measurements. Human epidermal growth factor receptor 2 (HER2) protein expression was measured in five different cell lines with HER2 expression from undetectable with immunohistochemistry to strong positive staining (IHC 3+). Repeatability, reproducibility, robustness, linearity, dynamic range, sensitivity, and quantification limits were evaluated. Reproducibility and robustness were assessed in a setup to resemble daily work in a laboratory using a commercial immunohistochemistry platform. In addition, qIHC was correlated to standard HER2 immunohistochemistry in 44 breast cancer specimens. For all evaluated parameters, qIHC performance was either comparable or better than the reference methods. Furthermore, qIHC has a lower limit of detection than both immunohistochemistry and the ELISA reference method, and demonstrated ability to measure HER2 accurately and precise within a large dynamic range. In conclusion, the results show that qIHC provides a sensitive, quantitative, accurate, and robust assay for measurement of protein expression in formalin-fixed, paraffin-embedded cell lines, and tissue.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27767098     DOI: 10.1038/modpathol.2016.176

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  67 in total

Review 1.  Current status of HER2 testing: caught between a rock and a hard place.

Authors:  S J Schnitt; T W Jacobs
Journal:  Am J Clin Pathol       Date:  2001-12       Impact factor: 2.493

2.  HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques.

Authors:  C M Ellis; M J Dyson; T J Stephenson; E L Maltby
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

3.  Observer variability in the interpretation of HER2/neu immunohistochemical expression with unaided and computer-aided digital microscopy.

Authors:  Marios A Gavrielides; Brandon D Gallas; Petra Lenz; Aldo Badano; Stephen M Hewitt
Journal:  Arch Pathol Lab Med       Date:  2011-02       Impact factor: 5.534

4.  What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard.

Authors:  Shinobu Umemura; R Yoshiyuki Osamura; Futoshi Akiyama; Keiichi Honma; Masafumi Kurosumi; Hironobu Sasano; Satoshi Toyoshima; Hitoshi Tsuda; Josef Rüschoff; Goi Sakamoto
Journal:  Am J Clin Pathol       Date:  2008-12       Impact factor: 2.493

5.  Bridging the gap: moving predictive and prognostic assays from research to clinical use.

Authors:  P Michael Williams; Tracy G Lively; J Milburn Jessup; Barbara A Conley
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

6.  Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.

Authors:  Maureen Cronin; Chithra Sangli; Mei-Lan Liu; Mylan Pho; Debjani Dutta; Anhthu Nguyen; Jennie Jeong; Jenny Wu; Kim Clark Langone; Drew Watson
Journal:  Clin Chem       Date:  2007-04-26       Impact factor: 8.327

7.  HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment.

Authors:  John J Barron; Mark J Cziraky; Thomas Weisman; David G Hicks
Journal:  Oncologist       Date:  2009-08-14

8.  Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors: a single institution experience.

Authors:  R Torrisi; C A Garcia-Etienne; A Losurdo; E Morenghi; L Di Tommaso; W Gatzemeier; A Sagona; B Fernandes; C Rossetti; M Eboli; A Rubino; E Barbieri; C Andreoli; S Orefice; C Gandini; S Rota; M Zuradelli; G Masci; A Santoro; C Tinterri
Journal:  Breast       Date:  2013-05-03       Impact factor: 4.380

9.  Validation of diagnostic accuracy using digital slides in routine histopathology.

Authors:  László Fónyad; Tibor Krenács; Péter Nagy; Attila Zalatnai; Judit Csomor; Zoltán Sápi; Judit Pápay; Júlia Schönléber; Csaba Diczházi; Béla Molnár
Journal:  Diagn Pathol       Date:  2012-03-31       Impact factor: 2.644

10.  Computer-assisted assessment of the human epidermal growth factor receptor 2 immunohistochemical assay in imaged histologic sections using a membrane isolation algorithm and quantitative analysis of positive controls.

Authors:  Bonnie H Hall; Monica Ianosi-Irimie; Parisa Javidian; Wenjin Chen; Shridar Ganesan; David J Foran
Journal:  BMC Med Imaging       Date:  2008-06-05       Impact factor: 1.930

View more
  17 in total

1.  Characterization of Plasma Membrane Localization and Phosphorylation Status of Organic Anion Transporting Polypeptide (OATP) 1B1 c.521 T>C Nonsynonymous Single-Nucleotide Polymorphism.

Authors:  Alexandra Crowe; Wei Zheng; Jonathan Miller; Sonia Pahwa; Khondoker Alam; Kar-Ming Fung; Erin Rubin; Feng Yin; Kai Ding; Wei Yue
Journal:  Pharm Res       Date:  2019-05-15       Impact factor: 4.200

2.  Microfluidic and Static Organotypic Culture Systems to Support Ex Vivo Spermatogenesis From Prepubertal Porcine Testicular Tissue: A Comparative Study.

Authors:  Marc Kanbar; Francesca de Michele; Jonathan Poels; Stéphanie Van Loo; Maria Grazia Giudice; Tristan Gilet; Christine Wyns
Journal:  Front Physiol       Date:  2022-06-02       Impact factor: 4.755

3.  Cosuppression of NF-κB and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer.

Authors:  Min-Kyung Yeo; Yoonjoo Kim; Da Hye Lee; Chaeuk Chung; Go Eun Bae
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

4.  MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.

Authors:  Eun Young Kang; Joshua Millstein; Gordana Popovic; Nicola S Meagher; Adelyn Bolithon; Aline Talhouk; Derek S Chiu; Michael S Anglesio; Betty Leung; Katrina Tang; Neil Lambie; Marina Pavanello; Annalyn Da-Anoy; Diether Lambrechts; Liselore Loverix; Siel Olbrecht; Christiani Bisinotto; Jesus Garcia-Donas; Sergio Ruiz-Llorente; Monica Yagüe-Fernandez; Robert P Edwards; Esther Elishaev; Alexander Olawaiye; Sarah Taylor; Beyhan Ataseven; Andreas du Bois; Philipp Harter; Jenny Lester; Claus K Høgdall; Sebastian M Armasu; Yajue Huang; Robert A Vierkant; Chen Wang; Stacey J Winham; Sabine Heublein; Felix K F Kommoss; Daniel W Cramer; Naoko Sasamoto; Lilian van-Wagensveld; Maria Lycke; Constantina Mateoiu; Janine Joseph; Malcolm C Pike; Kunle Odunsi; Chiu-Chen Tseng; Celeste L Pearce; Sanela Bilic; Thomas P Conrads; Arndt Hartmann; Alexander Hein; Michael E Jones; Yee Leung; Matthias W Beckmann; Matthias Ruebner; Minouk J Schoemaker; Kathryn L Terry; Mona A El-Bahrawy; Penny Coulson; John L Etter; Katherine LaVigne-Mager; Juergen Andress; Marcel Grube; Anna Fischer; Nina Neudeck; Greg Robertson; Rhonda Farrell; Ellen Barlow; Carmel Quinn; Anusha Hettiaratchi; Yovanni Casablanca; Ramona Erber; Colin J R Stewart; Adeline Tan; Yu Yu; Jessica Boros; Alison H Brand; Paul R Harnett; Catherine J Kennedy; Nikilyn Nevins; Terry Morgan; Peter A Fasching; Ignace Vergote; Anthony J Swerdlow; Francisco J Candido Dos Reis; G Larry Maxwell; Susan L Neuhausen; Arantzazu Barquin-Garcia; Francesmary Modugno; Kirsten B Moysich; Philip J Crowe; Akira Hirasawa; Florian Heitz; Beth Y Karlan; Ellen L Goode; Peter Sinn; Hugo M Horlings; Estrid Høgdall; Karin Sundfeldt; Stefan Kommoss; Annette Staebler; Anna H Wu; Paul A Cohen; Anna DeFazio; Cheng-Han Lee; Helen Steed; Nhu D Le; Simon A Gayther; Kate Lawrenson; Paul D P Pharoah; Gottfried Konecny; Linda S Cook; Susan J Ramus; Linda E Kelemen; Martin Köbel
Journal:  Virchows Arch       Date:  2021-11-15       Impact factor: 4.535

5.  A naturally derived small molecule PSM0537 targets the AF1Q-TCF4 interaction to suppress COX2 expression and inhibit cell proliferation and metastasis in osteosarcoma.

Authors:  Ning Duan; Wentao Zhang; Tao Song; Zhong Li; Xun Chen; Wei Ma
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

6.  Overexpression of CAV3 facilitates bone formation via the Wnt signaling pathway in osteoporotic rats.

Authors:  Run-Bao Yang; Feng-Fei Lin; Jun Yang; Bin Chen; Ming-Hua Zhang; Qiao-Ping Lu; Bo Xiao; Yan Liu; Ke Zheng; Yong-Rong Qiu
Journal:  Endocrine       Date:  2018-11-14       Impact factor: 3.925

7.  QuantISH: RNA in situ hybridization image analysis framework for quantifying cell type-specific target RNA expression and variability.

Authors:  Anni Virtanen; Sampsa Hautaniemi; Sanaz Jamalzadeh; Antti Häkkinen; Noora Andersson; Kaisa Huhtinen; Anna Laury; Sakari Hietanen; Johanna Hynninen; Jaana Oikkonen; Olli Carpén
Journal:  Lab Invest       Date:  2022-02-15       Impact factor: 5.502

8.  APNG as a prognostic marker in patients with glioblastoma.

Authors:  Sigurd Fosmark; Sofie Hellwege; Rikke H Dahlrot; Kristian L Jensen; Helene Derand; Jesper Lohse; Mia D Sørensen; Steinbjørn Hansen; Bjarne W Kristensen
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

9.  Semi-quantitative Determination of Protein Expression using Immunohistochemistry Staining and Analysis: An Integrated Protocol.

Authors:  Alexandra R Crowe; Wei Yue
Journal:  Bio Protoc       Date:  2019-12-20

10.  Expression and prognostic value of CXCL12/CXCR4/CXCR7 axis in clear cell renal cell carcinoma.

Authors:  Milena Potić Floranović; Ana Ristić Petrović; Filip Veličković; Ljubinka Janković Veličković
Journal:  Clin Exp Nephrol       Date:  2021-06-09       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.